Abstract：
This Viewpoint discusses direct-to-consumer biomarker tests for Alzheimer disease and their implications on future insurance coverage.
摘要：
本观点讨论了阿尔茨海默病的直接面向消费者的生物标志物测试及其对未来保险范围的影响。
